SPHK2 and hepatocellular carcinoma: Because the previous results suggested that enhanced SphK2 expression may be a cause of acquired resistance to regorafenib in HCC cells, we attempted to knock down SphK2 in 97H-R and 7721-R cells to determine whether regorafenib resistance could be reversed.